retatrutide mechanism retatrutide clinical trials trial Clinical Trial – My Endo Consult Retatrutide UK Guide: Key Facts

The realistic timeline Based on the current state of the clinical program, regulatory precedent, and publicly available information from Eli Lilly, here is the most realistic projection: Mid to late 2026: Remaining TRIUMPH, TRANSCEND, and SYNERGY Phase 3 results are reported

does not currently offer access to treatment services for Type 2 diabetes

GLP-1 Analogues Market Key Takeaways In terms of revenue, the global GLP-1 analogues market was valued at USD 66.48 billion in 2025

Proportion of participants achieving at least 5% body weight loss at the end of the treatment period

Our approach is different from other programs because it combines cutting-edge medications with ongoing support (both in person and through virtual appointments), setting you up for long-term success